Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adele Rike

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Transplantation|February 18, 2014
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belataceptJill C Krisl, Rita R Alloway, Adele Rike Shields, et al.
Clinical Transplants|April 12, 2007
Establishment of a nationalized, multiregional Paired Donation NetworkE Steve Woodle, David Goldfarb, Mark Aeder, et al.
Clinical Transplantation|March 14, 2014
Desensitization in kidney transplantation: review and future perspectivesBassam G Abu Jawdeh, Madison C Cuffy, Rita R Alloway, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 25, 2019
A prospective, iterative, adaptive trial of carfilzomib-based desensitizationSimon Tremblay, James J Driscoll, Adele Rike-Shields, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 8, 2021
Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter TrialDixon B Kaufman, E Steve Woodle, Adele Rike Shields, et al.
Transplantation|April 10, 2015
Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft SurvivalJill C Krisl, Rita R Alloway, Adele Rike Shield, et al.
Transplantation|May 28, 2011
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibitionR Carlin Walsh, Paul Brailey, Alin Girnita, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 5, 2023
Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidatesAmy P Rossi, Simon Tremblay, Cyd M Castro-Rojas, et al.
Clinical Transplants|July 22, 2008
Corticosteroid elimination: the Cincinnati experienceE Steve Woodle, Rita Alloway, Adele Rike, et al.
Clinical Transplantation|July 24, 2025
Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT-EXT Pharmacokinetic AnalysisAlexandra Pyatt, Melissa McGowan, Ryota Tanaka, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Transplantation|February 18, 2014
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belataceptJill C Krisl, Rita R Alloway, Adele Rike Shields, et al.
Clinical Transplants|April 12, 2007
Establishment of a nationalized, multiregional Paired Donation NetworkE Steve Woodle, David Goldfarb, Mark Aeder, et al.
Clinical Transplantation|March 14, 2014
Desensitization in kidney transplantation: review and future perspectivesBassam G Abu Jawdeh, Madison C Cuffy, Rita R Alloway, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 25, 2019
A prospective, iterative, adaptive trial of carfilzomib-based desensitizationSimon Tremblay, James J Driscoll, Adele Rike-Shields, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 8, 2021
Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter TrialDixon B Kaufman, E Steve Woodle, Adele Rike Shields, et al.
Transplantation|April 10, 2015
Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft SurvivalJill C Krisl, Rita R Alloway, Adele Rike Shield, et al.
Transplantation|May 28, 2011
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibitionR Carlin Walsh, Paul Brailey, Alin Girnita, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 5, 2023
Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidatesAmy P Rossi, Simon Tremblay, Cyd M Castro-Rojas, et al.
Clinical Transplants|July 22, 2008
Corticosteroid elimination: the Cincinnati experienceE Steve Woodle, Rita Alloway, Adele Rike, et al.
Clinical Transplantation|July 24, 2025
Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT-EXT Pharmacokinetic AnalysisAlexandra Pyatt, Melissa McGowan, Ryota Tanaka, et al.
Pageof 2